WO2015193667A1 - Use of cannabinoids in the treatment of epilepsy - Google Patents
Use of cannabinoids in the treatment of epilepsy Download PDFInfo
- Publication number
- WO2015193667A1 WO2015193667A1 PCT/GB2015/051775 GB2015051775W WO2015193667A1 WO 2015193667 A1 WO2015193667 A1 WO 2015193667A1 GB 2015051775 W GB2015051775 W GB 2015051775W WO 2015193667 A1 WO2015193667 A1 WO 2015193667A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cbd
- epilepsy
- treatment
- aed
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of "treatment-resistant epilepsy" (TRE).
- CBD cannabidiol
- TRE treatment-resistant epilepsy
- the patients suffering from TRE are children and young adults.
- CBD appears particularly effective when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES).
- FIRES febrile infection related epilepsy syndrome
- the reduction of total convulsive frequency has surprisingly been shown to be greater than 50%, through 70% to greater than 90% in a significant number of patients. Indeed a significant number of patients have been seizure free at the end of three months treatment.
- the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w) and the other
- tetrahydrocannabinol THC
- CBD tetrahydrocannabinol
- the CBD is used concomitantly with one or more other anti-epileptic drugs (AED).
- AED anti-epileptic drugs
- the CBD may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form.
- the CBD is formulated for administration separately, sequentially or
- Epilepsy occurs in approximately 1 % of the population worldwide, (Thurman et al., 201 1) of which 70% are able to adequately control their symptoms with the available existing anti-epileptic drugs (AED). However, 30% of this patient group, (Eadie et al., 2012), are unable to obtain seizure freedom from the AED that are available and as such are termed as suffering from "treatment-resistant epilepsy” (TRE).
- TRE treatment-resistant epilepsy
- Treatment-resistant epilepsy was defined in 2009 by the International League against Epilepsy (ILAE) as "failure of adequate trials of two tolerated and appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom" (Kwan et al., 2009).
- ILAE International League against Epilepsy
- Individuals who develop epilepsy during the first few years of life are often difficult to treat and as such are often termed treatment-resistant. Children who undergo frequent seizures in childhood are often left with neurological damage which can cause cognitive, behavioral and motor delays.
- Childhood epilepsy is a relatively common neurological disorder in children and young adults with a prevalence of approximately 700 per 100,000. This is twice the number of epileptic adults per population.
- Dravet syndrome One such childhood epilepsy is Dravet syndrome. Onset of Dravet syndrome almost always occurs during the first year of life with clonic and tonic-clonic seizures in previously healthy and developmental ⁇ normal infants (Dravet, 201 1). Symptoms peak at about five months of age. Other seizures develop between one and four years of age such as prolonged focal dyscognitive seizures and brief absence seizures.
- Seizures progress to be frequent and treatment-resistant, meaning that the seizures do not respond well to treatment. They also tend to be prolonged, lasting more than 5 minutes. Prolonged seizures may lead to status epilepticus, which is a seizure that lasts more than 30 minutes, or seizures that occur in clusters, one after another.
- Prognosis is poor and approximately 14% of children die during a seizure, because of infection, or suddenly due to uncertain causes, often because of the relentless neurological decline. Patients develop intellectual disability and life-long ongoing seizures. Intellectual impairment varies from severe in 50% patients, to moderate and mild intellectual disability each accounting for 25% of cases.
- anticonvulsants clobazam, clonazepam, levetiracetam, topiramate and valproic acid.
- stiripentol is approved in Europe for the treatment of Dravet syndrome in conjunction with clobazam and valproic acid. In the US, stiripentol was granted an Orphan Designation for the treatment of Dravet syndrome in 2008; however, the drug is not FDA approved.
- Potent sodium channel blockers used to treat epilepsy actually increase seizure frequency in patients with Dravet Syndrome.
- the most common are phenytoin,
- Management may also include a ketogenic diet, and physical and vagus nerve stimulation.
- anti-convulsive drugs many patients with Dravet syndrome are treated with anti-psychotic drugs, stimulants, and drugs to treat insomnia.
- CBD non-psychoactive cannabinoid cannabidiol
- CBD cannabidiol
- TRE treatment-resistant epilepsy
- FIRES febrile infection related epilepsy syndrome
- CBD cannabidiol
- the epilepsy is a treatment- resistant epilepsy (TRE)
- the CBD is present in an amount that reduces total convulsive seizure frequency by greater than 50% with respect to the seizure frequency achieved on concomitant anti-epileptic drugs (AED).
- the CBD is used in combination with two or more concomitant anti- epileptic drugs (AED).
- AED concomitant anti- epileptic drugs
- the CBD may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form.
- the seizure type to be treated is a complex partial seizure (focal seizure with impairment).
- the CBD is present in an amount that reduces total convulsive seizure frequency by greater than 70% with respect to the seizure frequency achieved on concomitant anti-epileptic drugs (AED). More preferably the CBD is present in an amount that reduces total convulsive seizure frequency by greater than 90% with respect to the seizure frequency achieved on concomitant anti-epileptic drugs (AED). More preferably still the CBD is present in an amount that reduces total convulsive seizure frequency by 100% with respect to the seizure frequency achieved on concomitant anti-epileptic drugs (AED).
- the CBD is present as a highly purified extract of cannabis which comprises at least 98% (w/w) CBD.
- the one or more AED is preferably selected from the group consisting of:
- clobazam levetiracetam; topiramate; stiripentol; phenobarbital; lacsamide; valproic acid;
- the CBD is used in combination with clobazam.
- the number of different anti-epileptic drugs or the dose of AED that are used in combination with the CBD is reduced. More preferably the dose of AED which is reduced is of clobazam.
- the dose of CBD is greater than 5 mg/kg/day.
- a dose of greater than 75mg of CBD per day would be provided.
- Doses greater than 5mg/kg/day such as greater than 10/mg/kg/day, greater than 15 mg/kg/day, greater than 20mg/kg/day and greater than 25 mg/kg/day are also envisaged to be effective.
- a method of treating treatment-resistant epilepsy comprising administering cannabidiol (CBD) to a subject, wherein the epilepsy is febrile infection related epilepsy syndrome (FIRES).
- CBD cannabidiol
- FIRES febrile infection related epilepsy syndrome
- a method of treating treatment-resistant epilepsy comprising administering cannabidiol (CBD) to a subject in an amount sufficient to reduce total convulsive seizure frequency by greater than 50% with respect to the seizure frequency achieved on one or more concomitant anti-epileptic drugs (AED).
- CBD cannabidiol
- CBDA Cannabidiolic acid
- CBDV Cannabidivarin
- Phytocannabinoids Phytocannabinoids; Endocannabinoids and Synthetic cannabinoids (which may be novel cannabinoids or synthetically produced phytocannabinoids or endocannabinoids).
- phytocannabinoids are cannabinoids that originate from nature and can be found in the cannabis plant.
- the phytocannabinoids can be isolated from plants to produce a highly purified extract or can be reproduced synthetically.
- “Highly purified cannabinoids” are defined as cannabinoids that have been extracted from the cannabis plant and purified to the extent that other cannabinoids and non- cannabinoid components that are co-extracted with the cannabinoids have been removed, such that the highly purified cannabinoid is greater than or equal to 98% (w/w) pure.
- Synthetic cannabinoids are compounds that have a cannabinoid or cannabinoid-like structure and are manufactured using chemical means rather than by the plant.
- Phytocannabinoids can be obtained as either the neutral (decarboxylated form) or the carboxylic acid form depending on the method used to extract the cannabinoids. For example it is known that heating the carboxylic acid form will cause most of the carboxylic acid form to decarboxylate into the neutral form.
- “Treatment-resistant epilepsy” TRE is defined as per the ILAE guidance of 2009 as epilepsy that is not adequately controlled by trials of one or more AED.
- Childhood epilepsy refers to the many different syndromes and genetic mutations that can occur to cause epilepsy in childhood. Examples of some of these are as follows: Dravet Syndrome; Myoclonic-Absence Epilepsy; Lennox-Gastaut syndrome; Generalized Epilepsy of unknown origin; CDKL5 mutation; Aicardi syndrome; bilateral polymicrogyria; Dup15q; SNAP25; and febrile infection related epilepsy syndrome (FIRES); benign rolandic epilepsy; juvenile myoclonic epilepsy; infantile spasm (West syndrome); and Landau-Kleffner syndrome. The list above is non-exhaustive as many different childhood epilepsies exist.
- the drug substance used in the trials is a liquid carbon dioxide extract of high-CBD containing chemotypes of Cannabis sativa L. which had been further purified by a solvent crystallization method to yield CBD.
- the crystallisation process specifically removes other cannabinoids and plant components to yield greater than 98% CBD.
- Cannabis sativa L. plants are grown, harvested, and processed to produce a botanical extract (intermediate) and then purified by crystallization to yield the CBD (drug substance).
- the plant starting material is referred to as Botanical Raw Material (BRM); the botanical extract is the intermediate; and the active pharmaceutical ingredient (API) is CBD, the drug substance.
- BRM Botanical Raw Material
- API active pharmaceutical ingredient
- the purity of the CBD drug substance achieved is greater than 98%.
- the possible impurities are related cannabinoids: CBDA, CBDV, CBD-C4 and THC.
- Distinct chemotypes of Cannabis sativa L. plant have been produced to maximize the output of the specific chemical constituents, the cannabinoids.
- One type of plant produces predominantly CBD. Only the (-)-trans isomer occurs naturally, furthermore during purification the stereochemistry of CBD is not affected. Production of the Intermediate
- Decarboxylation of CBDA to CBD was carried out using a large Heraeus tray oven.
- the decarboxylation batch size in the Heraeus is approximately 15 Kg. Trays were placed in the oven and heated to 105°C; the BRM took 96.25 minutes to reach 105 °C. Held at 105°C for 15 Minutes. Oven then set to 150°C; the BRM took 75.7 minutes to reach 150°C; BRM held at 150°C for 130 Minutes. Total time in the oven was 380 Minutes, including 45 minutes cooling and 15 Minutes venting.
- Extraction No 1 was performed using liquid C0 2 at 60 bar / 10°C to produce botanical drug substance (BDS) which was used for crystallisation to produce the test material.
- BDS botanical drug substance
- the crude CBD BDS was winterised in Extraction No 2 under standard conditions (2 volumes of ethanol at minus 20°C for around 50 hours). The precipitated waxes were removed by filtration and the solvent evaporated using the rotary evaporator (water bath up to 60°C) to yield the BDS.
- CBD cannabinoid in the cannabis plant. Previous studies in animals have demonstrated that CBD has anticonvulsant efficacy in multiple species and models.
- Example 1 describes data produced in an expanded access treatment program in children with TRE.
- Examples 2 to 4 demonstrates the efficacy of CBD in children with Dravet syndrome, myoclonic absence seizures and FIRES respectively.
- EXAMPLE 1 EFFICACY OF CANNABIDIOL IN CHILDREN AND YOUNG ADULTS WITH TREATMENT-RESISTANT EPILEPSY
- CBD cannabidiol
- the patients then received a highly purified CBD extract (greater than 98% CBD w/w) in sesame oil, of known and constant composition, at a dose of 5 mg/kg/day in addition to their baseline anti-epileptic drug (AED) regimen.
- AED anti-epileptic drug
- the daily dose was gradually increased by 2 to 5mg/kg increments until intolerance occurred or a maximum dose of 25 mg/kg/day was achieved.
- hematologic, liver, kidney function, and concomitant AED levels was performed at baseline, and after 4, 8 and 12 weeks of CBD therapy.
- the OR evaluates whether the odds of a certain event or outcome is the same for two groups. Specifically, the OR measures the ratio of the odds that an event or result will occur to the odds of the event not happening. An OR greater than 1 signifies that patients treated with a combination of CBD with dobazam will have a better odds of having a positive reduction in seizures than if they were not taking this combination of medications.
- the median number of seizures that these patients suffered from before starting treatment was 30 seizures per month, with a range of 4 to 2,800 seizures per month being recorded.
- Table 2 shows that after 3 months of therapy, 48% of patients had an equal to or greater than >50% reduction in seizures.
- CBD significantly reduces the number of seizures in a high proportion of patients that do not respond well to existing AED.
- the cannabidiol was generally well-tolerated in doses up to 25mg/kg/day.
- EXAMPLE 2 EFFICACY OF CANNABIDIOL IN CHILDREN AND YOUNG ADULTS WITH TREATMENT RESISTANT DRAVET SYNDROME
- levetiracetam levetiracetam; topiramate; stiripentol; phenobarbital; lacsamide; valproic acid; and zonisamide.
- the average number of concomitant antiepileptic drugs being taken was 2.7.
- the mean number of seizures that these patients suffered from before starting treatment was 35 seizures per month, with a range of 6 to 1 12 seizures per month recorded.
- Table 3 shows that after 3 months of therapy, 56% of patients had an equal to or greater than 50% reduction in seizures, a third had a 90% reduction and remarkably 22%, were entirely free from seizures at the three month stage.
- EXAMPLE 3 EFFICACY OF CANNABIDIOL IN CHILDREN AND YOUNG ADULTS WITH TREATMENT RESISTANT MYOCLONIC ABSENCE SEIZURES
- Table 4 shows that after 3 months of therapy, half of the patients had an equal to or greater than 50% reduction in seizures, one patient (25%) had a 90% reduction at the three month stage.
- EXAMPLE 4 EFFICACY OF CANNABIDIOL IN CHILDREN WITH TREATMENT RESISTANT FEBRILE INFECTION RELATED EPILEPY SYNDROME (FIRES)
- FIRES Febrile Infection Related Epilepsy Syndrome
- This syndrome occurs in previously healthy children with 66-100% of survivors becoming developmental ⁇ disabled. The mortality rate is up to 30%. There is a critical need for new therapies to treat this condition.
- a highly purified extract of CBD as an oral solution in sesame oil was used at a concentration of 25 mg/mL.
- Treatment was initiated at a dose of 10 mg/kg/day given in two divided doses, increasing by 5 mg/kg/day every 3 days.
- CBD vagus nerve stimulation therapy.
- anti-epileptic drugs including: levetiracetam, clobazam, perampanel, phenobarbital, phenytoin, carbamezapine, felbamate, ketogenic diet, lamotrigine, valproic acid and vagus nerve stimulation therapy.
- CBD treatment was very well tolerated and associated with a dramatic and nearly immediate greater than 90% improvement in clinical and electrographic seizure burden in two of the three children with refractory seizures or status epilepticus due to FIRES.
- Table 6 summarises the data obtained in the three sub-sets: Dravet syndrome; myoclonic absence seizures (MAS) and febrile infection related epilepsy syndrome (FIRES) after 12 weeks of treatment which have been described in the Examples 2 to 4 above. In addition the data for the remainder of the patients with other epilepsy syndromes are detailed. These data which exclude the patients with Dravet, MAS and FIRES show a far lower responder rate than for the specified sub-sets of the above specified sub-sets of epilepsy.
- Dravet syndrome myoclonic absence seizures
- FIRES febrile infection related epilepsy syndrome
- the responder rate for patients obtaining a greater than 90% reduction in their seizures is reduced from 33% in Dravet patients to only 8% in the unspecified group. This suggests that patients suffering from a TRE of sub-type Dravet syndrome, myoclonic absence seizures or FIRES will respond better to treatment with highly purified CBD than patients with other epilepsy sub-types.
- Dravet C The core Dravet syndrome phenotype. Epilepsia. 2011 Apr;52 Suppl 2:3-9.
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15732886.5A EP3157511B1 (en) | 2014-06-17 | 2015-06-17 | Use of cannabinoids in the treatment of epilepsy |
NZ727509A NZ727509A (en) | 2014-06-17 | 2015-06-17 | Use of cannabinoids in the treatment of epilepsy |
CA2952994A CA2952994C (en) | 2014-06-17 | 2015-06-17 | Use of cannabinoids in the treatment of epilepsy |
PL15732886T PL3157511T3 (en) | 2014-06-17 | 2015-06-17 | Use of cannabinoids in the treatment of epilepsy |
ES15732886.5T ES2680679T3 (en) | 2014-06-17 | 2015-06-17 | Use of cannabinoids in the treatment of epilepsy |
AU2015275886A AU2015275886A1 (en) | 2014-06-17 | 2015-06-17 | Use of cannabinoids in the treatment of epilepsy |
BR112016029506A BR112016029506A2 (en) | 2014-06-17 | 2015-06-17 | cannabidiol; and, method for treating treatment resistant epilepsy. |
MX2016016459A MX367338B (en) | 2014-06-17 | 2015-06-17 | Use of cannabinoids in the treatment of epilepsy. |
JP2016573558A JP6654282B2 (en) | 2014-06-17 | 2015-06-17 | Use of cannabinoids in the treatment of epilepsy |
AU2020220135A AU2020220135B2 (en) | 2014-06-17 | 2020-08-20 | Use of cannabinoids in the treatment of epilepsy |
AU2022202119A AU2022202119B2 (en) | 2014-06-17 | 2022-03-29 | Use of cannabinoids in the treatment of epilepsy |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1410771.8 | 2014-06-17 | ||
GB1410771.8A GB2530001B (en) | 2014-06-17 | 2014-06-17 | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB1506550.1 | 2015-04-17 | ||
GB1506550.1A GB2531093A (en) | 2014-06-17 | 2015-04-17 | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015193667A1 true WO2015193667A1 (en) | 2015-12-23 |
Family
ID=51266718
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2015/051775 WO2015193667A1 (en) | 2014-06-17 | 2015-06-17 | Use of cannabinoids in the treatment of epilepsy |
PCT/GB2015/051776 WO2015193668A1 (en) | 2014-06-17 | 2015-06-17 | Use of cannabidiol in the treatment of epilepsy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2015/051776 WO2015193668A1 (en) | 2014-06-17 | 2015-06-17 | Use of cannabidiol in the treatment of epilepsy |
Country Status (12)
Country | Link |
---|---|
US (16) | US9474726B2 (en) |
EP (2) | EP3157511B1 (en) |
JP (8) | JP6655850B2 (en) |
AU (5) | AU2015275887A1 (en) |
BR (2) | BR112016029506A2 (en) |
CA (3) | CA2952858C (en) |
ES (2) | ES2680679T3 (en) |
GB (2) | GB2530001B (en) |
MX (6) | MX2016016460A (en) |
NZ (4) | NZ765231A (en) |
PL (2) | PL3157512T3 (en) |
WO (2) | WO2015193667A1 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9522123B2 (en) | 2009-07-03 | 2016-12-20 | Gw Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
EP3206679A1 (en) * | 2014-10-14 | 2017-08-23 | GW Pharma Limited | Use of cannabidiol in the treatment of epilepsy |
GB2548873A (en) * | 2016-03-31 | 2017-10-04 | Gw Res Ltd | Use of cannabinoids in treatment of epilepsy |
US10603288B2 (en) | 2014-06-17 | 2020-03-31 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
JP2020514282A (en) * | 2016-12-20 | 2020-05-21 | ティルレイ,インコーポレイティド | Novel cannabinoid compositions and methods of use |
WO2020109806A1 (en) | 2018-11-30 | 2020-06-04 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10709673B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10729665B2 (en) | 2011-09-29 | 2020-08-04 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
WO2020169960A1 (en) | 2019-02-22 | 2020-08-27 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10799467B2 (en) | 2010-03-30 | 2020-10-13 | Gw Pharma Limited | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
US10918608B2 (en) | 2014-10-14 | 2021-02-16 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US11065227B2 (en) | 2016-08-25 | 2021-07-20 | GW Research Limited | Use of cannabinoids in the treatment of multiple myeloma |
US11147783B2 (en) | 2015-08-10 | 2021-10-19 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11147776B2 (en) | 2014-06-27 | 2021-10-19 | GW Research Limited | 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
US11160795B2 (en) | 2020-02-27 | 2021-11-02 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
US11679087B2 (en) | 2016-12-16 | 2023-06-20 | GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome |
US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
US11865102B2 (en) | 2018-04-27 | 2024-01-09 | GW Research Limited | Cannabidiol preparations and its uses |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2377218A (en) * | 2001-05-04 | 2003-01-08 | Gw Pharmaceuticals Ltd | Process and apparatus for extraction of active substances and enriched extracts from natural products |
GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
US20170224634A1 (en) * | 2014-05-29 | 2017-08-10 | Insys Development Company, Inc. | Stable cannabinoid formulations |
US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
US11911361B2 (en) | 2014-05-29 | 2024-02-27 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
WO2016044370A1 (en) | 2014-09-16 | 2016-03-24 | India Globalization Capital, Inc. | Cannabinoid composition and method for treating pain |
GB2531280A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
CN107205960A (en) | 2014-10-21 | 2017-09-26 | 联合大麻公司 | Cannador and its preparation and application |
US10675207B2 (en) * | 2014-11-04 | 2020-06-09 | A Better Walker, Llc | Wrap around walking aid |
EP3247359A4 (en) | 2015-01-25 | 2018-08-08 | India Globalization Capital, Inc. | Composition and method for treating seizure disorders |
CA2981285A1 (en) * | 2015-04-01 | 2016-10-06 | India Globalization Capital, Inc. | Composition and method for treating seizure disorders |
AU2016255707A1 (en) * | 2015-04-28 | 2017-11-30 | The Regents Of The University Of California | Uses of cannabidiol for treatment of infantile spasms |
US10596159B2 (en) | 2015-08-12 | 2020-03-24 | India Globalization Capital, Inc. | Method and composition for treating cachexia and eating disorders |
US20170174614A1 (en) | 2015-12-22 | 2017-06-22 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
ES2861774T3 (en) | 2015-12-22 | 2021-10-06 | Zogenix International Ltd | Fenfluramine Compositions and Procedures for Making Them |
EP3251668A1 (en) | 2016-06-02 | 2017-12-06 | Pharmotech SA | Cannabidiol compositions and uses thereof |
WO2017218629A1 (en) | 2016-06-15 | 2017-12-21 | India Globalization Capital, Inc. | Method and composition for treating seizure disorders |
BR112019002538A2 (en) | 2016-08-11 | 2019-05-21 | Ovid Therapeutics Inc. | use of a pharmaceutical composition comprising an allosteric modulator, use of a pharmaceutical composition comprising garboxadol or a pharmaceutically acceptable salt thereof, and pharmaceutical composition for parenteral administration |
CN109689103A (en) * | 2016-08-24 | 2019-04-26 | 周格尼克斯国际有限公司 | For inhibiting 5-HT2BThe preparation and its application method of the formation of agonist |
US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
CA3062247A1 (en) * | 2017-05-09 | 2018-11-15 | Zogenix International Limited | Methods of treating doose syndrome using fenfluramine |
EP3638235A4 (en) | 2017-06-14 | 2021-06-09 | Trevena, Inc. | Compounds for modulating s1p1 activity and methods of using the same |
US20190022028A1 (en) * | 2017-07-21 | 2019-01-24 | Annabelle Manalo | Cannabidiol-enriched caprylic acid |
JOP20200045A1 (en) * | 2017-09-19 | 2020-02-27 | Zynerba Pharmaceuticals Inc | Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults |
US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
WO2019067413A1 (en) * | 2017-09-26 | 2019-04-04 | Zogenix International Limited | Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations |
GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
GB2568471B (en) * | 2017-11-15 | 2022-04-13 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2568929A (en) * | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2572737A (en) * | 2018-01-24 | 2019-10-16 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
CA3089994A1 (en) | 2018-01-31 | 2019-08-08 | Canopy Holdings, LLC | Hemp powder |
CA3097335A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
EP3806835A1 (en) | 2018-06-14 | 2021-04-21 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
JP2021536490A (en) * | 2018-09-05 | 2021-12-27 | ピュリシス・リミテッド・ライアビリティ・カンパニーPurisys LLC | Cannabidiol composition with a modified cannabinoid profile |
EP3864000A4 (en) | 2018-10-10 | 2022-08-10 | Treehouse Biosciences, Inc. | Synthesis of cannabigerol |
GB2579179A (en) * | 2018-11-21 | 2020-06-17 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
CN113874344A (en) * | 2019-03-08 | 2021-12-31 | 加利福尼亚大学董事会 | Use of 8, 9-dihydrocannabidiol compounds |
BR112022003959A2 (en) * | 2019-09-05 | 2022-05-24 | Trevena Inc | Methods for treating epilepsy |
GB2588461A (en) * | 2019-10-25 | 2021-04-28 | Gw Res Ltd | Use of cannabidiol preparations in the treatment of absence epilepsy |
MX2022005766A (en) | 2019-11-19 | 2022-08-08 | Trevena Inc | Compounds and methods of preparing compounds s1p1 modulators. |
GB201916977D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannibidol-type cannabinoid compound |
GB201918846D0 (en) * | 2019-12-19 | 2020-02-05 | Gw Res Ltd | Oral cannabinoid formulations |
US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
GB2597283A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
GB2597297A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
GB2597308A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
GB2597302A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with stroke or brain haemorrhage |
GB2597300A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
GB2597280A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with auriculotemporal syndrome |
GB2597307A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with encephalitis |
GB2597299A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
GB2597309A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
GB2597291A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
GB2597286A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes |
GB2597304A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome |
GB2597282A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
GB2597287A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
GB2597288A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
GB2597301A (en) | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with herpes simplex virus |
GB2598922A (en) * | 2020-09-18 | 2022-03-23 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
JP2024500611A (en) | 2020-12-23 | 2024-01-10 | エム-フォー、エルエルシー | Cannabinoid extraction and purification |
US11931369B1 (en) | 2023-07-24 | 2024-03-19 | Poviva Corp | Compositions and methods for treating epilepsy |
US11944635B1 (en) * | 2023-07-24 | 2024-04-02 | Poviva Corp | Compositions and methods for treating epilepsy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011001169A1 (en) * | 2009-07-03 | 2011-01-06 | Gw Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
Family Cites Families (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2304669A (en) | 1940-08-16 | 1942-12-08 | Adams Roger | Isolation of cannabidiol |
GB9726916D0 (en) | 1997-12-19 | 1998-02-18 | Danbiosyst Uk | Nasal formulation |
US6403126B1 (en) | 1999-05-26 | 2002-06-11 | Websar Innovations Inc. | Cannabinoid extraction method |
US6949582B1 (en) | 1999-05-27 | 2005-09-27 | Wallace Walter H | Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment |
IL136839A (en) | 2000-06-16 | 2006-12-10 | Yissum Res Dev Co | Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same |
NZ527289A (en) | 2001-02-14 | 2005-05-27 | Gw Pharma Ltd | Lipophilic medicaments and their administration via mucosal surfaces |
GB2381194A (en) | 2001-09-07 | 2003-04-30 | Gw Pharmaceuticals Ltd | Pharmaceutical formulations |
GB2380129B (en) | 2001-02-14 | 2004-08-11 | Gw Pharma Ltd | Pharmaceutical formulations |
US7025992B2 (en) | 2001-02-14 | 2006-04-11 | Gw Pharma Limited | Pharmaceutical formulations |
GB2377633A (en) | 2001-05-11 | 2003-01-22 | Gw Pharmaceuticals Ltd | Pharmaceutical compositions comprising the cannabinoids THC and CBD |
US7456183B2 (en) | 2001-04-09 | 2008-11-25 | Novartis Vaccines And Diagnostics, Inc. | Guanidino compounds |
GB2377218A (en) | 2001-05-04 | 2003-01-08 | Gw Pharmaceuticals Ltd | Process and apparatus for extraction of active substances and enriched extracts from natural products |
GB0202385D0 (en) | 2002-02-01 | 2002-03-20 | Gw Pharma Ltd | Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions |
ITPD20020138A1 (en) | 2002-05-24 | 2003-11-24 | Matteo Bevilacqua | COMPOSITION OF TERPENIC-BASED SUBSTANCES, METHOD OF PREPARATION AND METHOD OF DISPERSION IN THE ENVIRONMENT OF THE SAME. |
DE10226494A1 (en) | 2002-06-14 | 2004-01-08 | Lts Lohmann Therapie-Systeme Ag | Film-shaped mucoadhesive dosage forms for administration of cannabis active ingredients |
US10538373B2 (en) | 2002-08-14 | 2020-01-21 | Gw Pharma Limited | Pharmaceutical formulation |
US6946150B2 (en) | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
MXPA05001621A (en) | 2002-08-14 | 2005-08-19 | Gw Pharma Ltd | Improvements in the extraction of pharmaceutically active components from plant materials. |
WO2004016246A1 (en) | 2002-08-14 | 2004-02-26 | Gw Pharma Limited | Cannabinoid liquid formulations for mucosal amdinistration |
GB2393182B (en) * | 2002-09-23 | 2007-03-14 | Gw Pharma Ltd | Method of preparing cannabidiol from plant material |
GB0222077D0 (en) | 2002-09-23 | 2002-10-30 | Gw Pharma Ltd | Methods of preparing cannabinoids from plant material |
US20040110828A1 (en) | 2002-11-27 | 2004-06-10 | Chowdhury Dipak K. | Tetrahydrocannabinol compositions and methods of manufacture and use thereof |
CA2542417A1 (en) * | 2003-10-14 | 2005-04-28 | Neurologix Research, Inc. | Methods and compositions for the treatment of neurological disease |
WO2006017892A1 (en) | 2004-08-16 | 2006-02-23 | Northern Sydney And Central Coast Area Health Service | Methods for improving cognitive functioning |
AU2005305675B2 (en) | 2004-11-16 | 2012-12-13 | Gw Pharma Limited | New use for cannabinoid |
GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
TWI366460B (en) | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
US20070060638A1 (en) | 2005-08-26 | 2007-03-15 | Olmstead Mary C | Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist |
GB2432312A (en) | 2005-11-01 | 2007-05-23 | Gw Pharma Ltd | Pharmaceutical compositions for the treatment of pain |
GB2434312B (en) | 2006-01-18 | 2011-06-29 | Gw Pharma Ltd | Cannabinoid-containing plant extracts as neuroprotective agents |
US9877928B2 (en) | 2006-05-30 | 2018-01-30 | Air Systems, Inc. | Gear drive damper |
GB2438682A (en) | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
CA2659775A1 (en) | 2006-08-04 | 2008-02-14 | Insys Therapeutics Inc. | Aqueous dronabinol formulations |
WO2008021394A2 (en) | 2006-08-15 | 2008-02-21 | Theraquest Biosciences, Llc | Pharmaceutical formulations of cannabinoids and method of use |
US20110150825A1 (en) | 2006-11-14 | 2011-06-23 | Pharmacyclics, Inc. | Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions |
WO2008094181A2 (en) | 2007-02-01 | 2008-08-07 | The Regents Of The University Of Michigan | Compositions and methods for detecting, preventing and treating seizures and seizure related disorders |
CN101040855A (en) | 2007-04-12 | 2007-09-26 | 杨喜鸿 | Compound including rimonabant and poloxamer, solid dispersion and the preparation and the application of the medicine |
GB2448535A (en) | 2007-04-19 | 2008-10-22 | Gw Pharma Ltd | New use for cannabinoid-containing plant extracts |
WO2008144475A1 (en) | 2007-05-17 | 2008-11-27 | California Pacific Medical Center | Methods and compositions for treating cancer |
GB2449691A (en) | 2007-05-31 | 2008-12-03 | Gw Pharma Ltd | A reference plant lacking medicinal active compound expression |
EP2023121A1 (en) | 2007-07-06 | 2009-02-11 | Bp Oil International Limited | Optical cell |
GB2450753B (en) | 2007-07-06 | 2012-07-18 | Gw Pharma Ltd | New Pharmaceutical formulation |
US8293786B2 (en) | 2007-07-30 | 2012-10-23 | Alltranz Inc. | Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same |
US20090181080A1 (en) | 2007-08-06 | 2009-07-16 | Insys Therapeutics Inc. | Oral cannabinnoid liquid formulations and methods of treatment |
GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
GB2459637B (en) | 2008-01-21 | 2012-06-06 | Gw Pharma Ltd | New use for cannabinoids |
CA2719830C (en) * | 2008-03-26 | 2017-08-08 | Stichting Sanammad | Chewing gum compositions comprising cannabinoids |
GB2478074B (en) | 2008-06-04 | 2012-12-26 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
GB2478072B (en) | 2008-06-04 | 2012-12-26 | Gw Pharma Ltd | Anti-tumoural effects of cannabinoid combinations |
AU2009345154A1 (en) | 2009-04-29 | 2011-12-22 | University Of Kentucky Research Foundation | Cannabinoid-containing compositions and methods for their use |
ES2409055T3 (en) | 2009-06-29 | 2013-06-24 | Bender Analytical Holding B.V. | Drug delivery system comprising polyoxazoline and a bioactive agent |
US8735374B2 (en) | 2009-07-31 | 2014-05-27 | Intelgenx Corp. | Oral mucoadhesive dosage form |
GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
DE102010012281A1 (en) | 2010-03-22 | 2011-09-22 | Fresenius Medical Care Deutschland Gmbh | Pharmaceutical compositions containing substituted 6-deoxy-6-sulfanylcyclodextrin |
GB2487183B (en) | 2011-01-04 | 2018-10-03 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
GB2479153B (en) | 2010-03-30 | 2014-03-19 | Gw Pharma Ltd | The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy |
TWI583374B (en) | 2010-03-30 | 2017-05-21 | Gw伐瑪有限公司 | Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy |
EP2575765B1 (en) | 2010-06-07 | 2018-12-05 | Suda Ltd | Oral spray formulations and methods for administration of sildenafil citrate |
EP3459533A1 (en) | 2010-08-04 | 2019-03-27 | Grünenthal GmbH | Pharmaceutical dosage form comprising 6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for the treatment of nociceptive pain |
WO2012033478A1 (en) | 2010-09-07 | 2012-03-15 | Murty Pharmaceuticals, Inc. | An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery |
US8895537B2 (en) * | 2010-10-29 | 2014-11-25 | Infirst Healthcare Ltd. | Compositions and methods for treating cardiovascular diseases |
GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
CA2737447A1 (en) | 2011-04-27 | 2012-10-27 | Antony Paul Hornby | Hayley's comet |
GB2524689B (en) | 2011-05-20 | 2016-01-27 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
GB201111261D0 (en) | 2011-07-01 | 2011-08-17 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders |
EP2747770A1 (en) * | 2011-08-26 | 2014-07-02 | BIAL - Portela & Cª S.A. | Treatments involving eslicarbazepine acetate or eslicarbazepine |
GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
GB2496687A (en) | 2011-11-21 | 2013-05-22 | Gw Pharma Ltd | Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells |
US9254272B2 (en) | 2011-11-30 | 2016-02-09 | Sutter West Bay Hospitals | Resorcinol derivatives |
DE102012105063C5 (en) | 2012-06-12 | 2023-09-14 | Thc Pharm Gmbh The Health Concept | Stabilization of cannabinoids and their pharmaceutical preparations |
US9345771B2 (en) | 2012-10-04 | 2016-05-24 | Insys Development Company, Inc. | Oral cannabinoid formulations |
CN103110582A (en) | 2013-03-04 | 2013-05-22 | 上海医药工业研究院 | Cannabinol compound micro-emulsion and preparation method thereof |
MX2015013202A (en) | 2013-03-15 | 2016-04-07 | Biotech Inst Llc | Breeding, production, processing and use of specialty cannabis. |
US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
US20150181924A1 (en) * | 2013-10-31 | 2015-07-02 | Michael R. Llamas | Cannabidiol liquid composition for smoking |
US9259449B2 (en) | 2014-01-07 | 2016-02-16 | Joshua Michael Raderman | Method for modifying THC content in a lipid-based extract of cannabis |
WO2015142501A1 (en) * | 2014-03-21 | 2015-09-24 | Bodybio Inc. | Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids |
US20170224634A1 (en) | 2014-05-29 | 2017-08-10 | Insys Development Company, Inc. | Stable cannabinoid formulations |
US11331279B2 (en) | 2014-05-29 | 2022-05-17 | Radius Pharmaceuticals, Inc. | Stable cannabinoid formulations |
NZ726746A (en) * | 2014-05-29 | 2020-08-28 | Fresh Cut Dev Llc | Stable cannabinoid formulations |
WO2015187988A1 (en) | 2014-06-04 | 2015-12-10 | Intellimedix | Composition and methods of treating epilepsy and/or epilepsy-related disorders |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
WO2016022936A1 (en) | 2014-08-07 | 2016-02-11 | Murty Pharmaceuticals, Inc. | An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts |
CA2859934A1 (en) | 2014-09-22 | 2016-03-22 | A. Paul Hornby | Hayley's comet ii |
GB2531280A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
CN107205960A (en) | 2014-10-21 | 2017-09-26 | 联合大麻公司 | Cannador and its preparation and application |
US20180303791A1 (en) | 2014-11-26 | 2018-10-25 | One World Cannabis Ltd | Synergistic use of cannabis for treating multiple myeloma |
US10172786B2 (en) | 2014-12-16 | 2019-01-08 | Axim Biotechnologies, Inc. | Oral care composition comprising cannabinoids |
EP3247359A4 (en) | 2015-01-25 | 2018-08-08 | India Globalization Capital, Inc. | Composition and method for treating seizure disorders |
EP3270896A4 (en) | 2015-03-19 | 2018-09-12 | One World Cannabis Ltd. | Preparations of cannabis emulsions and methods thereof |
US20180185324A1 (en) | 2015-06-11 | 2018-07-05 | One World Cannabis Ltd | Novel cannabinoid combination therapies for multiple myeloma (mm) |
GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
GB2551985B (en) | 2016-07-01 | 2019-01-30 | Gw Res Ltd | Novel formulation |
GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
US10925525B2 (en) | 2017-08-18 | 2021-02-23 | Canon U.S.A., Inc. | Combined pulse oximetry and diffusing wave spectroscopy system and control method therefor |
GB201715919D0 (en) | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
GB2568471B (en) | 2017-11-15 | 2022-04-13 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2572125B (en) | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
GB2572126B (en) | 2018-01-03 | 2021-01-13 | Gw Res Ltd | Pharmaceutical |
GB2572737A (en) | 2018-01-24 | 2019-10-16 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
GB2579179A (en) | 2018-11-21 | 2020-06-17 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
GB2580881A (en) | 2018-11-30 | 2020-08-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2580653A (en) | 2019-01-21 | 2020-07-29 | Gw Res Ltd | Use of cannabinoids in the treatment of comorbidities associated with epilepsy |
GB2581517A (en) | 2019-02-22 | 2020-08-26 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2581987B (en) | 2019-03-06 | 2021-11-17 | Gw Res Ltd | Use of cannabidiol in combination with antibiotics |
GB2584140A (en) | 2019-05-23 | 2020-11-25 | Gw Res Ltd | Use of cannabidiol in the treatment of epileptic spasms |
GB2584341B (en) | 2019-05-31 | 2023-03-01 | Gw Res Ltd | Cannabinoid formulations |
GB2586026A (en) | 2019-07-29 | 2021-02-03 | Gw Res Ltd | Use of cannabidol in the treatment of Dravet syndrome |
GB2588576A (en) | 2019-08-27 | 2021-05-05 | Gw Res Ltd | Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease |
GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
GB201916977D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannibidol-type cannabinoid compound |
GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
GB201918846D0 (en) | 2019-12-19 | 2020-02-05 | Gw Res Ltd | Oral cannabinoid formulations |
GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
US20220087951A1 (en) | 2020-09-18 | 2022-03-24 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
-
2014
- 2014-06-17 GB GB1410771.8A patent/GB2530001B/en active Active
-
2015
- 2015-04-17 GB GB1506550.1A patent/GB2531093A/en not_active Withdrawn
- 2015-06-17 PL PL15732887T patent/PL3157512T3/en unknown
- 2015-06-17 ES ES15732886.5T patent/ES2680679T3/en active Active
- 2015-06-17 CA CA2952858A patent/CA2952858C/en active Active
- 2015-06-17 JP JP2016573518A patent/JP6655850B2/en active Active
- 2015-06-17 EP EP15732886.5A patent/EP3157511B1/en active Active
- 2015-06-17 ES ES15732887.3T patent/ES2680656T3/en active Active
- 2015-06-17 WO PCT/GB2015/051775 patent/WO2015193667A1/en active Application Filing
- 2015-06-17 AU AU2015275887A patent/AU2015275887A1/en not_active Abandoned
- 2015-06-17 NZ NZ765231A patent/NZ765231A/en unknown
- 2015-06-17 NZ NZ727509A patent/NZ727509A/en unknown
- 2015-06-17 NZ NZ765223A patent/NZ765223A/en unknown
- 2015-06-17 CA CA3157008A patent/CA3157008A1/en active Pending
- 2015-06-17 PL PL15732886T patent/PL3157511T3/en unknown
- 2015-06-17 MX MX2016016460A patent/MX2016016460A/en active IP Right Grant
- 2015-06-17 US US14/741,783 patent/US9474726B2/en active Active
- 2015-06-17 CA CA2952994A patent/CA2952994C/en active Active
- 2015-06-17 WO PCT/GB2015/051776 patent/WO2015193668A1/en active Application Filing
- 2015-06-17 US US14/741,829 patent/US11311498B2/en active Active
- 2015-06-17 JP JP2016573558A patent/JP6654282B2/en active Active
- 2015-06-17 AU AU2015275886A patent/AU2015275886A1/en not_active Abandoned
- 2015-06-17 EP EP15732887.3A patent/EP3157512B1/en active Active
- 2015-06-17 BR BR112016029506A patent/BR112016029506A2/en not_active Application Discontinuation
- 2015-06-17 BR BR112016029498A patent/BR112016029498A2/en not_active Application Discontinuation
- 2015-06-17 MX MX2020003182A patent/MX2020003182A/en unknown
- 2015-06-17 MX MX2016016459A patent/MX367338B/en active IP Right Grant
- 2015-06-17 NZ NZ727511A patent/NZ727511A/en unknown
-
2016
- 2016-10-04 US US15/284,766 patent/US9949936B2/en active Active
- 2016-12-13 MX MX2022008278A patent/MX2022008278A/en unknown
- 2016-12-13 MX MX2019008337A patent/MX2019008337A/en unknown
- 2016-12-13 MX MX2022004851A patent/MX2022004851A/en unknown
-
2017
- 2017-03-03 US US15/449,124 patent/US9956184B2/en active Active
- 2017-03-03 US US15/449,177 patent/US9956185B2/en active Active
- 2017-03-03 US US15/449,204 patent/US9956186B2/en active Active
- 2017-03-03 US US15/449,084 patent/US9956183B2/en active Active
- 2017-03-03 US US15/449,185 patent/US9949937B2/en active Active
-
2018
- 2018-04-09 US US15/948,412 patent/US10603288B2/en active Active
-
2019
- 2019-11-22 JP JP2019211265A patent/JP7010915B2/en active Active
-
2020
- 2020-01-31 JP JP2020014572A patent/JP6919000B2/en active Active
- 2020-02-14 US US16/791,940 patent/US20200179303A1/en not_active Abandoned
- 2020-08-10 US US16/989,605 patent/US20200368179A1/en not_active Abandoned
- 2020-08-13 AU AU2020217417A patent/AU2020217417A1/en not_active Abandoned
- 2020-08-20 AU AU2020220135A patent/AU2020220135B2/en active Active
- 2020-12-11 US US17/119,873 patent/US11154516B2/en active Active
-
2021
- 2021-07-21 JP JP2021120246A patent/JP7238037B2/en active Active
- 2021-09-10 US US17/472,016 patent/US11701330B2/en active Active
-
2022
- 2022-01-12 JP JP2022002833A patent/JP7371139B2/en active Active
- 2022-03-08 US US17/689,607 patent/US20220202738A1/en active Pending
- 2022-03-29 AU AU2022202119A patent/AU2022202119B2/en active Active
- 2022-07-29 US US17/816,349 patent/US11766411B2/en active Active
-
2023
- 2023-01-26 JP JP2023010188A patent/JP2023061964A/en active Pending
- 2023-05-19 US US18/320,906 patent/US20230301936A1/en active Pending
- 2023-10-18 JP JP2023179226A patent/JP2024020210A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011001169A1 (en) * | 2009-07-03 | 2011-01-06 | Gw Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
Non-Patent Citations (5)
Title |
---|
ANONYMOUS: "GWPharma - GW Pharmaceuticals Announces Physician Reports of Epidiolex Treatment Effect in Children and Young Adults with Treatment-Resistant Epilepsy from Physician-Led Expanded Access Treatment Program", 17 June 2014 (2014-06-17), XP055205379, Retrieved from the Internet <URL:http://www.gwpharm.com/GW%20Pharmaceuticals%20Announces%20Physician%20Reports%20of%20Epidiolex%20Treatment%20Effect%20in%20Children%20and%20Young%20Adults%20with%20Treatment-Resistant%20Epilepsy%20from%20Physician-Led%20Expanded%20Access%20Treatment%20Program.aspx> [retrieved on 20150729] * |
CUNHA J M ET AL: "Chronic administration of cannabidiol to healthy volunteers and epileptic patients", PHARMACOLOGY, S. KARGER AG, CH, vol. 21, no. 3, 1 January 1980 (1980-01-01), pages 175 - 185, XP009139434, ISSN: 0031-7012, DOI: 10.1159/000137430 * |
EDWARD MAA ET AL: "The case for medical marijuana in epilepsy", EPILEPSIA, vol. 55, no. 6, 22 May 2014 (2014-05-22), pages 783 - 786, XP055205357, ISSN: 0013-9580, DOI: 10.1111/epi.12610 * |
PORTER BRENDA E ET AL: "Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy", EPILEPSY AND BEHAVIOR, vol. 29, no. 3, 10 May 2013 (2013-05-10), pages 574 - 577, XP028775189, ISSN: 1525-5050, DOI: 10.1016/J.YEBEH.2013.08.037 * |
URI KRAMER ET AL: "Febrile infection-related epilepsy syndrome (FIRES): Pathogenesis, treatment, and outcome", EPILEPSIA, vol. 52, no. 11, 1 November 2011 (2011-11-01), pages 1956 - 1965, XP055206176, ISSN: 0013-9580, DOI: 10.1111/j.1528-1167.2011.03250.x * |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9522123B2 (en) | 2009-07-03 | 2016-12-20 | Gw Pharma Limited | Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy |
US10799467B2 (en) | 2010-03-30 | 2020-10-13 | Gw Pharma Limited | Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy |
US11318109B2 (en) | 2011-09-29 | 2022-05-03 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
US10729665B2 (en) | 2011-09-29 | 2020-08-04 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
US11766411B2 (en) | 2014-06-17 | 2023-09-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11701330B2 (en) | 2014-06-17 | 2023-07-18 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11311498B2 (en) | 2014-06-17 | 2022-04-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11154516B2 (en) | 2014-06-17 | 2021-10-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10603288B2 (en) | 2014-06-17 | 2020-03-31 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11793770B2 (en) | 2014-06-27 | 2023-10-24 | GW Research Limited | 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy |
US11147776B2 (en) | 2014-06-27 | 2021-10-19 | GW Research Limited | 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy |
US10709674B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10918608B2 (en) | 2014-10-14 | 2021-02-16 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US10709673B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
EP3206679A1 (en) * | 2014-10-14 | 2017-08-23 | GW Pharma Limited | Use of cannabidiol in the treatment of epilepsy |
US10765643B2 (en) | 2014-10-14 | 2020-09-08 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US11633369B2 (en) | 2014-10-14 | 2023-04-25 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
EP3206679B1 (en) * | 2014-10-14 | 2022-11-30 | GW Research Limited | Use of cannabidiol in the treatment of aicardi syndrome |
US11446258B2 (en) | 2014-10-14 | 2022-09-20 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10966939B2 (en) | 2014-10-14 | 2021-04-06 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11065209B2 (en) | 2014-10-14 | 2021-07-20 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US11400055B2 (en) | 2014-10-14 | 2022-08-02 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US11096905B2 (en) | 2014-10-14 | 2021-08-24 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11154517B2 (en) | 2014-10-14 | 2021-10-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
EP3984531A1 (en) | 2015-06-17 | 2022-04-20 | GW Research Limited | Use of cannabidiol for the treatment of focal seizures in dravet syndrome |
WO2016203239A1 (en) * | 2015-06-17 | 2016-12-22 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10709671B2 (en) | 2015-06-17 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11357741B2 (en) | 2015-06-17 | 2022-06-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
US11147783B2 (en) | 2015-08-10 | 2021-10-19 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
WO2017168138A1 (en) * | 2016-03-31 | 2017-10-05 | GW Research Limited | Use of cannabinoids in the treatment of sturge weber syndrome |
GB2548873A (en) * | 2016-03-31 | 2017-10-04 | Gw Res Ltd | Use of cannabinoids in treatment of epilepsy |
US10583096B2 (en) | 2016-03-31 | 2020-03-10 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
GB2548873B (en) * | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
US11065227B2 (en) | 2016-08-25 | 2021-07-20 | GW Research Limited | Use of cannabinoids in the treatment of multiple myeloma |
US11679087B2 (en) | 2016-12-16 | 2023-06-20 | GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome |
JP2020514282A (en) * | 2016-12-20 | 2020-05-21 | ティルレイ,インコーポレイティド | Novel cannabinoid compositions and methods of use |
US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
US11865102B2 (en) | 2018-04-27 | 2024-01-09 | GW Research Limited | Cannabidiol preparations and its uses |
WO2020109806A1 (en) | 2018-11-30 | 2020-06-04 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
WO2020169960A1 (en) | 2019-02-22 | 2020-08-27 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11160795B2 (en) | 2020-02-27 | 2021-11-02 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
US11406623B2 (en) | 2020-02-27 | 2022-08-09 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2022202119B2 (en) | Use of cannabinoids in the treatment of epilepsy | |
AU2015332208B2 (en) | Use of cannabidiol in the treatment of Tuberous Sclerosis Complex | |
GB2531282A (en) | Use of cannabinoids in the treatment of epilepsy | |
GB2531280A (en) | Use of cannabidiol in the treatment of intractable epilepsy | |
GB2531278A (en) | Use of cannabidiol in the treatment of intractable epilepsy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15732886 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/016459 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2016573558 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2952994 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015732886 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015732886 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016029506 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2015275886 Country of ref document: AU Date of ref document: 20150617 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112016029506 Country of ref document: BR Kind code of ref document: A2 Effective date: 20161215 |